FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1520966044> ?p ?o ?g. }

• W1520966044 endingPage "269" @default.
• W1520966044 startingPage "265" @default.
• W1520966044 abstract "Aims To evaluate the resistance to oxidation of human lipoproteins after hypolipidaemic therapy. Methods VLDL and LDL samples were obtained from patients with Familial Combined Hyperlipidaemia included in a randomized, double‐blind, cross‐over study, with 8 weeks of active treatment (gemfibrozil, 600 mg twice daily, or lovastatin, 40 mg daily) and a 4‐week wash‐out period. Oxidation related analytes after Cu‐induced oxidation of VLDL and LDL have been investigated. Further, in order to relate possible changes in oxidative behaviour to lipoprotein composition, the proportion of the lipid species transported by lipoproteins (triglycerides, phospholipids, and cholesteryl esters), the molar composition of fatty acids for each lipoprotein lipid, and the content of antioxidant vitamins in plasma (vitamin C) and lipoproteins (vitamin E) have been studied. Results Both drugs reduced the plasma concentration of apo‐B lipoproteins (−23% gemfibrozil, −26% lovastatin), but whereas lovastatin affected mainly LDL‐cholesterol (−30%), gemfibrozil reduced triglycerides (−49%) and VLDL‐cholesterol (−48%). Lovastatin treatment had no effect on the lipid and protein composition, the fatty acid profile, or the vitamin E content of either VLDL or LDL; likewise, lipoprotein oxidation markers (Cu‐induced conjugated dienes, thiobarbituric acid reactive substances formation, and lysine residues) were similar before and after lovastatin treatment. Gemfibrozil therapy also had no effect on lipoprotein oxidation; nevertheless, it consistently: a) decreased the proportion of LDL‐triglycerides (−32%), and b) increased the proportion (molar%) of 18:3 n‐6 in VLDL triglycerides (+140%), phospholipids (+363%) and cholesteryl esters (+53%). Conclusions Based on these results, lovastatin and gemfibrozil do not adversely affect lipoprotein oxidation in patients with mixed dyslipidaemia. In the case of gemfibrozil, this occurs in spite of an increased proportion of some polyunsaturated fatty acids in VLDL. In the context of a fixed dietary intake, such modifications suggest that the drug influences liver enzyme activities involved in fatty acid chain synthesis (elongases and desaturases)." @default.
• W1520966044 created "2016-06-24" @default.
• W1520966044 creator A5007079141 @default.
• W1520966044 creator A5030130509 @default.
• W1520966044 creator A5035352022 @default.
• W1520966044 creator A5043446902 @default.
• W1520966044 creator A5048779913 @default.
• W1520966044 creator A5054806908 @default.
• W1520966044 creator A5072466845 @default.
• W1520966044 date "1998-03-01" @default.
• W1520966044 modified "2023-10-16" @default.
• W1520966044 title "Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia" @default.
• W1520966044 cites W1933275042 @default.
• W1520966044 cites W1964199710 @default.
• W1520966044 cites W1965721108 @default.
• W1520966044 cites W1986594943 @default.
• W1520966044 cites W1991160610 @default.
• W1520966044 cites W1991395678 @default.
• W1520966044 cites W1993851808 @default.
• W1520966044 cites W1994191432 @default.
• W1520966044 cites W2002438078 @default.
• W1520966044 cites W2041470954 @default.
• W1520966044 cites W2054028557 @default.
• W1520966044 cites W2065211595 @default.
• W1520966044 cites W2065742333 @default.
• W1520966044 cites W2067632733 @default.
• W1520966044 cites W2068627985 @default.
• W1520966044 cites W2076575421 @default.
• W1520966044 cites W2088550457 @default.
• W1520966044 cites W2089286420 @default.
• W1520966044 cites W2092101873 @default.
• W1520966044 cites W2128635872 @default.
• W1520966044 cites W2148439889 @default.
• W1520966044 cites W2170781044 @default.
• W1520966044 cites W4244067656 @default.
• W1520966044 cites W4249771824 @default.
• W1520966044 cites W4293247451 @default.
• W1520966044 cites W4320805883 @default.
• W1520966044 doi "https://doi.org/10.1046/j.1365-2125.1998.00672.x" @default.
• W1520966044 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1873371" @default.
• W1520966044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9517370" @default.
• W1520966044 hasPublicationYear "1998" @default.
• W1520966044 type Work @default.
• W1520966044 sameAs 1520966044 @default.
• W1520966044 citedByCount "12" @default.
• W1520966044 crossrefType "journal-article" @default.
• W1520966044 hasAuthorship W1520966044A5007079141 @default.
• W1520966044 hasAuthorship W1520966044A5030130509 @default.
• W1520966044 hasAuthorship W1520966044A5035352022 @default.
• W1520966044 hasAuthorship W1520966044A5043446902 @default.
• W1520966044 hasAuthorship W1520966044A5048779913 @default.
• W1520966044 hasAuthorship W1520966044A5054806908 @default.
• W1520966044 hasAuthorship W1520966044A5072466845 @default.
• W1520966044 hasBestOaLocation W15209660442 @default.
• W1520966044 hasConcept C126322002 @default.
• W1520966044 hasConcept C134018914 @default.
• W1520966044 hasConcept C185592680 @default.
• W1520966044 hasConcept C2776448209 @default.
• W1520966044 hasConcept C2776940978 @default.
• W1520966044 hasConcept C2777551382 @default.
• W1520966044 hasConcept C2778004101 @default.
• W1520966044 hasConcept C2778163477 @default.
• W1520966044 hasConcept C2778670441 @default.
• W1520966044 hasConcept C2779091943 @default.
• W1520966044 hasConcept C2780072125 @default.
• W1520966044 hasConcept C2780940807 @default.
• W1520966044 hasConcept C55493867 @default.
• W1520966044 hasConcept C555293320 @default.
• W1520966044 hasConcept C71924100 @default.
• W1520966044 hasConcept C8243546 @default.
• W1520966044 hasConceptScore W1520966044C126322002 @default.
• W1520966044 hasConceptScore W1520966044C134018914 @default.
• W1520966044 hasConceptScore W1520966044C185592680 @default.
• W1520966044 hasConceptScore W1520966044C2776448209 @default.
• W1520966044 hasConceptScore W1520966044C2776940978 @default.
• W1520966044 hasConceptScore W1520966044C2777551382 @default.
• W1520966044 hasConceptScore W1520966044C2778004101 @default.
• W1520966044 hasConceptScore W1520966044C2778163477 @default.
• W1520966044 hasConceptScore W1520966044C2778670441 @default.
• W1520966044 hasConceptScore W1520966044C2779091943 @default.
• W1520966044 hasConceptScore W1520966044C2780072125 @default.
• W1520966044 hasConceptScore W1520966044C2780940807 @default.
• W1520966044 hasConceptScore W1520966044C55493867 @default.
• W1520966044 hasConceptScore W1520966044C555293320 @default.
• W1520966044 hasConceptScore W1520966044C71924100 @default.
• W1520966044 hasConceptScore W1520966044C8243546 @default.
• W1520966044 hasIssue "3" @default.
• W1520966044 hasLocation W15209660441 @default.
• W1520966044 hasLocation W15209660442 @default.
• W1520966044 hasLocation W15209660443 @default.
• W1520966044 hasLocation W15209660444 @default.
• W1520966044 hasOpenAccess W1520966044 @default.
• W1520966044 hasPrimaryLocation W15209660441 @default.
• W1520966044 hasRelatedWork W1520966044 @default.
• W1520966044 hasRelatedWork W1976602105 @default.
• W1520966044 hasRelatedWork W1990547751 @default.
• W1520966044 hasRelatedWork W2030404799 @default.
• W1520966044 hasRelatedWork W2067406978 @default.

• next